Literature DB >> 21343465

Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.

Athanasios Chatzimoschou1, Aspasia Katragkou, Maria Simitsopoulou, Charalampos Antachopoulos, Elpiniki Georgiadou, Thomas J Walsh, Emmanuel Roilides.   

Abstract

Biofilm formation complicates the treatment of various infections caused by Candida species. We investigated the effects of simultaneous or sequential combinations of two triazoles, voriconazole (VRC) and posaconazole (PSC), with two echinocandins, anidulafungin (AND) and caspofungin (CAS), against Candida albicans and Candida parapsilosis biofilms in comparison to their planktonic counterparts. Antifungal activity was assessed by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide (XTT) metabolic assay. Antifungal-agent interactions were analyzed by the Bliss independence model in the simultaneous-treatment studies and by analysis of variance (ANOVA) in the sequential-treatment studies. Against C. albicans planktonic cells, the simultaneous combination of PSC (32 to 128 mg/liter) and CAS (0.008 to 0.25 mg/liter) was synergistic; the combinations of PSC (128 to 1,024 mg/liter) with AND (0.03 to 0.5 mg/liter) and VRC (32 to 512 mg/liter) with AND (0.008 to 0.03 mg/liter) were antagonistic. Against C. parapsilosis planktonic cells, the interaction between VRC (32 to 1,024 mg/liter) and CAS (1 to 16 mg/liter) was antagonistic. All simultaneous antifungal combinations demonstrated indifferent interactions against biofilms of both Candida species. Damage to biofilms of both species increased (P<0.01) in the presence of subinhibitory concentrations of echinocandins (0.008 to 0.064 mg/liter), followed by the addition of PSC (512 mg/liter for C. albicans and 64 to 512 mg/liter for C. parapsilosis) or VRC (256 to 512 mg/liter for C. albicans and 512 mg/liter for C. parapsilosis). Triazole-echinocandin combinations do not appear to produce antagonistic effects against Candida sp. biofilms, while various significant interactions occur with their planktonic counterparts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21343465      PMCID: PMC3088240          DOI: 10.1128/AAC.00959-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia.

Authors:  Frank C Odds
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

2.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 4.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

Review 5.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses.

Authors:  Yukihiro Kaneko; Hideaki Ohno; Hidesuke Fukazawa; Yuko Murakami; Yoshifumi Imamura; Shigeru Kohno; Yoshitsugu Miyazaki
Journal:  Med Mycol       Date:  2010-06       Impact factor: 4.076

7.  Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy.

Authors:  Matthew K Schinabeck; Lisa A Long; Mohammad A Hossain; Jyotsna Chandra; Pranab K Mukherjee; Sotohy Mohamed; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Antifungal combinations against Candida albicans biofilms in vitro.

Authors:  Stefano P Bachmann; Gordon Ramage; Kacy VandeWalle; Thomas F Patterson; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Toward more effective antifungal therapy: the prospects of combination therapy.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

10.  Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.

Authors:  A M Tortorano; J Peman; H Bernhardt; L Klingspor; C C Kibbler; O Faure; E Biraghi; E Canton; K Zimmermann; S Seaton; R Grillot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-17       Impact factor: 3.267

View more
  11 in total

1.  Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa.

Authors:  Athanasios Chatzimoschou; Maria Simitsopoulou; Charalampos Antachopoulos; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Authors:  Aspasia Katragkou; Matthew McCarthy; Joseph Meletiadis; Vidmantas Petraitis; Patriss W Moradi; Gittel E Strauss; Monique M Fouant; Laura L Kovanda; Ruta Petraitiene; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

3.  Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Authors:  Maria Simitsopoulou; Pavla Peshkova; Efthymia Tasina; Aspasia Katragkou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

4.  In-vitro Inhibition of Biofilm Formation in Candida albicans and Candida tropicalis by Heat Stable Compounds in Culture Filtrate of Aspergillus flavus.

Authors:  Sayan Bhattacharyya; Prashant Gupta; Gopa Banerjee; Amita Jain; Mastan Singh
Journal:  J Clin Diagn Res       Date:  2013-10-05

Review 5.  Antifungal lock therapy.

Authors:  Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

6.  In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms.

Authors:  Aspasia Katragkou; Matthew McCarthy; Elizabeth L Alexander; Charalampos Antachopoulos; Joseph Meletiadis; Mary Ann Jabra-Rizk; Vidmantas Petraitis; Emmanuel Roilides; Thomas J Walsh
Journal:  J Antimicrob Chemother       Date:  2014-10-06       Impact factor: 5.790

7.  A Screen for Small Molecules to Target Candida albicans Biofilms.

Authors:  Matthew B Lohse; Craig L Ennis; Nairi Hartooni; Alexander D Johnson; Clarissa J Nobile
Journal:  J Fungi (Basel)       Date:  2020-12-27

8.  Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of Scedosporium and Fusarium spp.

Authors:  Katerina Vikelouda; Maria Simitsopoulou; Lemonia Skoura; Charalampos Antachopoulos; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

9.  Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.

Authors:  Ying-Lien Chen; Virginia N Lehman; Anna F Averette; John R Perfect; Joseph Heitman
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Relationship between antifungal susceptibility profile and virulence factors in Candida albicans isolated from nail specimens.

Authors:  Faezeh Mohammadi; Zeinab Ghasemi; Behnaz Familsatarian; Eelham Salehi; Somayeh Sharifynia; Ameneh Barikani; Monirsadat Mirzadeh; Mohammad Ali Hosseini
Journal:  Rev Soc Bras Med Trop       Date:  2020-02-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.